Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17577501 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL383249 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL26554037 | 0.89 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL121732 | 0.89 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19399430 | 0.89 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12259056 | 0.89 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL16940283 | 0.89 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL21563023 | 0.89 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL25966278 | 0.89 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL24879407 | 0.88 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIRNA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738308-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage (3dT) | SIN3A, NSUN3, AGO2 | SLC28A1 378/4885SLC28A2 361/4885SLC29A1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.